Current concepts in refractory migraine

Current Treatment Options in Neurology

Volumn 15, Issue 1, 2013, Pages 40-55

  Schulman, Elliott ^a   McGeeney, Brian E ^b  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abortive; Anticonvulsants; Anxiety; Classification; Definition; Depression; Dopamine antagonists; Intractable; Migraine; Nerve blocks; Neurostimulation; Opioids; Prophylaxis; Refractory; Risk factors; Sleep disorders; Supplements; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; AMITRIPTYLINE; ANALGESIC AGENT; BOTULINUM TOXIN A; CAFFEINE; CELECOXIB; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE; ERGOTAMINE DERIVATIVE; FLURBIPROFEN; FROVATRIPTAN; IBUPROFEN; INDOMETACIN; KETOROLAC; MONOAMINE OXIDASE A INHIBITOR; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PROMETHAZINE; RIZATRIPTAN; SUMATRIPTAN; TOPIRAMATE; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VENLAFAXINE; ZOLMITRIPTAN;

ARTICLE; CHILD ABUSE; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DIZZINESS; DOCTOR PATIENT RELATION; DROWSINESS; DRUG COST; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; DYSGEUSIA; FEEDBACK SYSTEM; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; HYPOTENSION; INTERNATIONAL CLASSIFICATION OF HEADACHE DISORDERS II; INTERPERSONAL COMMUNICATION; KIDNEY DISEASE; LEG CRAMP; LEISURE; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; MIGRAINE; MIGRAINE DISABILITY ASSESSMENT; MOOD; MOOD DISORDER; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NECK PAIN; NEPHROLITHIASIS; NERVE BLOCK; NERVE STIMULATION; OBESITY; PARESTHESIA; PATIENT CARE; PATIENT COMPLIANCE; PHYSICAL ABUSE; QUALITY OF LIFE; REFRACTORY MIGRAINE; SEDATION; SEXUAL ABUSE; SIDE EFFECT; SLEEP; SLEEP DISORDER; STRESS MANAGEMENT; TACHYCARDIA; THORAX PAIN; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT PLANNING; URINE RETENTION; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 84873090904     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-012-0206-5     Document Type: Article

References (49)

1. Goadsby P, Schoenen J, Ferrari M, et al. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006;26:1168-70.
2. Schulman EA, Lake III AE, Goadsby PJ, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache J Head Face Pain. 2008;48:778-82.
3. Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache J Head Face Pain. 2010;50:1499-506.
4. Robbins L. Refractory headache definition. Headache J Head Face Pain. 2011;51:310-1.
5. Robbins L. Refractory chronic migraine: long-term follow-up using a refractory rating scale. J Headache Pain. 2012;13:225-9.
6. Schulman EA, Lipton R, Peterlin BL, et al. Commentary from the refractory headache special interest section on defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache J Head Face Pain. 2010;50:1637-9.
7. Irimia P, Palma JA, Fernandez-Torron R, Martinez-Vila E. Refractory migraine in a headache clinic population. BMC Neurol. 2011;11:94.
8. Busch V, Gaul C. Exercise in migraine therapy-is there any evidence for efficacy? A critical review. Headache. 2008;48:890-9.
9. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;46:1334-43.
10. Lipton R, Diamond M, Freitag F, et al. Migraine prevention patterns in a community sample: Results from the American Migraine Prevalence and Prevention (AMPP) study. Philadelphia: American Headache Society 47th Annual Scientific Meeting; 2005.
11. Loder E, Biondi D. General principles of migraine management: The changing role of prevention. Headache. 2005;45:S33-47.
12. Evans RW, Williams MA, Rapoport AM, Peterlin BL. The association of obesity with episodic and chronic migraine. Headache. 2012;52:663-71.
13. Peterlin BL. Bariatric surgery in obese migraineurs: Mounting evidence but important questions remain. Cephalalgia. 2011;31:1333-5.
14. Andress-Rothrock D, King W, Rothrock J. An analysis of migraine triggers in a clinic-based population. Headache. 2010;50:1366-70.
15. Sauro KM, Becker WJ. The stress and migraine interaction. Headache. 2009;49:1378-86.
16. Dodick DW, Eross EJ, Parish JM, Silber M. Clinical, anatomical, and physiologic relationship between sleep and headache. Headache. 2003;43:282-92.
17. Rains JC. Chronic headache and potentially modifiable risk factors: Screening and behavioral management of sleep disorders. Headache. 2008;48:32-9.
18. Rains JC, Poceta JS. Headache and sleep disorders: Review and clinical implications for headache management. Headache. 2006;46:1344-63.
19. Rains JC, Poceta JS. Sleep and headache. Curr Treat Options Neurol. 2010;12:1-15. A comprehensive review of sleep and how it applies to headache.
20. Sancisi E, Cevoli S, Vignatelli L, et al. Increased prevalence of sleep disorders in chronic headache: A case-control study. Headache. 2010;50:1464-72.
21. Griffiths R, Evans S, Heishman S, et al. Low-dose caffeine physical dependence in humans. J Pharmacol Exp Ther. 1990;255:1123-32.
22. Cripe SM, Sanchez SE, Gelaye B, et al. Association between intimate partner violence, migraine and probable migraine. Headache J Head Face Pain. 2011;51:208-19.
23. Tietjen GE, Brandes JL, Peterlin BL, et al. Childhood maltreatment and migraine (part I). Prevalence and adult revictimization: A multicenter headache clinic survey. Headache. 2009;50:20-31.
24. Tietjen GE, Brandes JL, Peterlin BL, et al. Childhood maltreatment and migraine (part II). Emotional abuse as a risk factor for headache chronification. Headache. 2009;50:32-41.
25. Tietjen GE, Brandes JL, Peterlin BL, et al. Childhood maltreatment and migraine (part III). Association with comorbid pain conditions. Headache. 2009;50:42-51.
26. McGeeney BE. Acute and urgent treatment of refractory migraine. In: Schulman EA, Levin M, Lake III AE, Loder E, editors. Refractory migraine. Mechanisms and management. New York: Oxford University Press; 2010. p. 116-35.A more comprehensive review of acute treatment in the refractory migraine patient.
27. Mathew NT. Prophylactic treatment of refractory migraine. In: Schulman EA, Levin M, Lake III AE, Loder E, editors. Refractory migraine. Mechanisms and management. 1st ed. New York: Oxford University Press; 2010. p. 101-15. A more comprehensie review of prophylactic treatment in the refractory migraine patient.
28. Sargent JD, Baumel B, Peters K, et al. Aborting a migraine attack: Naproxen sodium v ergotamine plus caffeine. Headache J Head Face Pain. 1988;28:263-6.
29. Silberstein SD, Freitag FG, Bigal ME. Migraine treatment. In: Silberstein S, Lipton RB, Dodick DE, editors. Wolf's headache and other head pain. 8th ed. New York: Oxford University Press; 2008. p. 177-292.
30. Scott AK. Dihydroergotamine: A review of its Use in the treatment of migraine and other headaches. Clin Neuropharmacol. 1992;15:289-96.
31. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995-7.
32. McGeeney BE. Dopamine antagonists and migraine. Drug Dev Res. 2007;68:341-5.
33. Jones J, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA J Am Med Assoc. 1989;261:1174-6.
34. Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: Meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336:1359-61.
35. Ziegler DK. Opioids in headache treatment: Is there a role? Neurol Clin. 1997;15:199-207.
36. Saper JR, Lake AE, Bain PA, et al. A practice guide for continuous opioid therapy for refractory daily headache: Patient selection, physician requirements, and treatment monitoring. Headache J Head Face Pain. 2010;50:1175-93.
37. Diener H, Bussone G, Oene JCV, et al. Topiramate reduces headache days in chronic migraine: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814-23.
38. Fontebasso M. Topiramate for migraine prophylaxis. Expert Opin Pharmacother. 2007;8:2811-23.
39. Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: Randomized, double-blind, crossover study. Clin Neurol Neurosurg. 2004;107:44-8.
40. Holland S, Silberstein S, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346-53.
41. Lipton RB, Gobel H, Einhaupl KM, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004;63:2240-4.
42. Ashkenazi A, Levin M. Nerve blocks, neurostimulation, and botulinum toxin injection treatment for refractory migraine. In: Schulman EA, Levin M, Lake III AE, Loder E, editors. Refractory migraine. Mechanisms and management. 1st ed. New York: Oxford University Press; 2010. p. 266-92.Excellent practical chapter on the nerve blocks for headache.
43. Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes-prolonged effects from a single injection. Pain. 2006;122:126-9.
44. Aurora S, Dodick D, Turkel C, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793-803.
45. Diener H, Dodick D, Aurora S, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804-14.
46. Lambru G, Matharu MS. Occipital nerve stimulation in primary headache syndromes. Ther Adv Neurol Disord. 2012;5:57-67.
47. Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. Lancet Neurol. 2012;11:708-19.
48. Saper JR, Lake III AE. Inpatient strategies for refractory migraine. In: Schulman EA, Levin M, Lake III AE, Loder E, editors. Refractory migraine: Mechanisms and management. New York: Oxford University Press; 2010. p. 341.This chapter, written by an expert in the field, provides an excellent overview of treating RM.
49. Schulman EA. Historical overview of refractory migraine. In: Schulman EA, Levin M, Lake III AE, Loder E, editors. Refractory migraine. Mechanisms and management. 1st ed. New York: Oxford University Press; 2010. p. 5-18.